See why Sapient is preferred among multi-omics companies for large-scale metabolomics and proteomics studies exploring the dynamic factors modulating disease and drug response.
While the vast majority of biomarker discovery to date has focused on genomics, >80% of disease risk stems from non-genetic factors and exposures over time. This molecular landscape has remained largely unexplored, until now.
Sapient’s innovative technologies finally enable rapid, large-scale multi-omics biomarker discovery beyond the genome.
We comprehensively profile metabolite, lipid, and protein biomarkers, which read out dynamic factors influencing health and disease – measuring thousands of biomarkers per sample, across thousands of samples at a time.
Capturing >15K small molecule biomarkers per biosample, including metabolites and lipids, with capacity to handle >5,000 samples per day.
Optimized approaches for interrogation of the plasma and tissue proteome, with our /Core/ Discovery method measuring 4,000+ proteins and PTMs in plasma.
Supported by an advanced biocomputational framework for analysis of multi-omics datasets, we deliver actionable insights to elucidate disease mechanisms, subtype diseases, and ultimately improve the precision and efficacy of therapies.
Explore our integrative services for rapid multi-omics data generation & analysis and how they deliver unique value to accelerate your studies.
"*" indicates required fields
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
© 2024 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY, and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
